


PHARMACEUTICAL 2019

CTI BIOPHARMA CORP Rank 188 of 363







PHARMACEUTICAL 2019

CTI BIOPHARMA CORP Rank 188 of 363



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 32% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 94%, being 57% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current | 82,492 |
| Cost of Goods Sold | 879 |
| Intangible Assets | 0 |
| Liabilities, Current | 23,055 |
| Liabilities, Non-Current | 13,838 |
| Other Assets | 5,547 |
| Other Compr. Net Income | -4,339 |
| Other Expenses | 660 |
| Other Liabilities | 0 |
| Other Net Income | 3,547 |
| Other Revenues | 26,290 |
| Property and Equipment | 1,793 |
| Research and Development | 36,467 |
| Selling, General and Administrative Expense | 21,183 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 89,832 |
| Liabilities | 36,893 |
| Expenses | 59,189 |
| Revenues | 26,290 |
| Stockholders Equity | 52,939 |
| Net Income | -29,352 |
| Comprehensive Net Income | -31,522 |
| Economic Capital Ratio | 94% |

